

US EPA ARCHIVE DOCUMENT

DATA EVALUATION RECORD - SUPPLEMENT

XDE-570 (FLORASULAM)

Study Type: Non-guideline; Preliminary Developmental Toxicity Study in Rats

Work Assignment No. 4-1-128 L (MRID 46808231)

Prepared for
Health Effects Division
Office of Pesticide Programs
U.S. Environmental Protection Agency
2777 South Crystal Drive
Arlington, VA 22202

Prepared by
Pesticides Health Effects Group
Sciences Division
Dynamac Corporation
1910 Sedwick Road, Bldg 100, Ste B.
Durham, NC 27713

Primary Reviewer
Michael E. Viana, Ph.D., D.A.B.T.

Signature: _____
Date: _____

Secondary Reviewer
John W. Allran, M.S.

Signature: _____
Date: _____

Program Manager:
Michael E. Viana, Ph.D., D.A.B.T.

Signature: _____
Date: _____

Quality Assurance:
Mary L. Menetrez, Ph.D.

Signature: _____
Date: _____

Disclaimer

This Data Evaluation Record may have been altered by the Health Effects Division subsequent to signing by Dynamac Corporation personnel

US EPA ARCHIVE DOCUMENT

XDE-570 (FLORASULAM)/129108

Non-guideline

EPA Reviewer: Karlyn J. Bailey Signature: _____

Registration Action Branch 2, Health Effects Division (7509P) Date: _____

Work Assignment Manager: Myron Ottley, Ph.D. Signature: _____

Registration Action Branch 3, Health Effects Division (7509P) Date: _____

Template version 02/06

DATA EVALUATION RECORD – SUPPLEMENT

See TXR # 0054348 for previous DER

This supplement contains:

- New cover page
- New executive summary

STUDY TYPE: Preliminary Prenatal Developmental Toxicity Study - Rats; Non-guideline**PC CODE:** 129108**DP BARCODE:** D331116**TXR#:** 0054348**TEST MATERIAL (PURITY):** XDE-570 (99.3% a.i.)**SYNONYMS:** Florasulam; *N*-(2,6-Difluorophenyl)-8-fluoro-5-methoxy(1,2,4)triazolo (1,5-*c*)pyrimidine-2-sulfonamide; XR-570; XRD-570; DE-570**CITATION:** Liberacki, A. B, Breslin, W. J., and K. E. Stebbins (1996) XDE-570: oral gavage teratology probe study CD rats. The Toxicology Research Laboratory, Health and Environmental Sciences, The Dow Chemical Company, Midland, MI. Laboratory Project Study ID: DR-0312-6565-024, June 12, 1996. MRID 46808231. Unpublished.**SPONSOR:** DowElanco, 9330 Zionsville Road, Indianapolis, IN**EXECUTIVE SUMMARY:** In a preliminary developmental toxicity study (MRID 46808231), XDE-570 (Florasulam; 99.3% a.i.; Lot No. 940714) in aqueous 0.5% methylcellulose was administered daily via oral gavage to ten time-mated CD rats/group at a dose volume of 4 mL/kg at dose levels of 0, 100, 500, or 1000 mg/kg/day from gestation day (GD) 6-15. Excessive maternal toxicity was observed in the 1000 mg/kg/day group, so two additional groups of ten rats were administered the test compound as previously described at dose levels of 0 or 750 mg/kg/day in order to more accurately determine the maximum tolerated dose. On GD 16, all surviving does were killed and a detailed necropsy was performed. The kidneys were removed and weighed, and the uterus and ovaries were removed and examined grossly for numbers of implantations, resorptions, and corpora lutea. Fetuses were not examined.

Five 1000 mg/kg/day dams were found dead on GD 10 (3 rats) and 13 (2 rats). Prior to death, two of these dams were observed with excessive chromorrhoea; and one also displayed decreased activity. Additionally at this dose, body weights were decreased ($p \leq 0.05$) by 7-8% on GD 9-12, resulting in a body weight loss on GD 6-9 (-3.8 g vs. 13.9 g in controls; $p \leq 0.05$) and decreased ($p \leq 0.05$) body weight gains on GD 9-12 (decr. 36%). Food consumption was also decreased (not significant [NS]) by 27% on GD 6-12. For these reasons, the surviving animals in this dose group were killed on GD 13 for humane reasons. No further data were collected or reported for this dose group.

In the remaining groups, no treatment-related effects were observed on mortality, clinical signs, or body weights. Gross pathology results were not provided for the 750 mg/kg/day group.

One 750 mg/kg/day dam was found dead on GD 15. This animal had no prior clinical signs of toxicity. At necropsy, this animal presented with decreased amounts of body fat, perineal soiling, hemolyzed blood in the digestive tract, erosions and/or ulcers in the stomach, and an enlarged spleen. The cause of death was attributed to a probable lymphoreticular tumor and uterine hemorrhage and was not considered treatment-related.

At 750 mg/kg/day, overall (GD 6-16) body weight gains were decreased (NS) by 14%, and food consumption was decreased by 5-10% during the treatment period. Additionally, absolute and relative (to body weight) kidney weights were increased ($p \leq 0.05$) by 12 and 16%, respectively.

The maternal LOAEL is 750 mg/kg/day, based on decreased body weight gains and food consumption, and increased kidney weights. The maternal NOAEL is 500 mg/kg/day.

There were no effects of treatment on the numbers of implantations, litters, or resorptions, or post-implantation losses. Fetal evaluations were not conducted.

The developmental LOAEL and NOAEL were not determined.

This study is classified **acceptable/non-guideline**.

COMPLIANCE: Signed and dated GLP Compliance, Quality Assurance, and Data Confidentiality statements were provided.